These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10113009)

  • 21. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The rate of development of new drugs in the United States, 1963 through 1975.
    Wardell WM; Hassar M; Anavekar SN; Lasagna L
    Clin Pharmacol Ther; 1978 Aug; 24(2):133-45. PubMed ID: 679593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Michigan lab axed as Pfizer cuts costs.
    Wadman M
    Nature; 2007 Feb; 445(7127):466-7. PubMed ID: 17268437
    [No Abstract]   [Full Text] [Related]  

  • 24. The importance of patent term restoration to pharmaceutical innovation.
    Hutt PB
    Health Aff (Millwood); 1982; 1(2):6-24. PubMed ID: 7185724
    [No Abstract]   [Full Text] [Related]  

  • 25. Estimating the cost of new drug development: is it really 802 million dollars?
    Adams CP; Brantner VV
    Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Market failure and the poverty of new drugs in maternal health.
    Fisk NM; Atun R
    PLoS Med; 2008 Jan; 5(1):e22. PubMed ID: 18215109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
    Moore TJ; Zhang H; Anderson G; Alexander GC
    JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Merck's recall of rofecoxib--a strategic perspective.
    Oberholzer-Gee F; Inamdar SN
    N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
    [No Abstract]   [Full Text] [Related]  

  • 29. A closer look at the returns and risk of pharmaceutical R&D.
    Joglekar P; Paterson ML
    J Health Econ; 1986 Jun; 5(2):153-77. PubMed ID: 10287224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018.
    Sertkaya A; Beleche T; Jessup A; Sommers BD
    JAMA Netw Open; 2024 Jun; 7(6):e2415445. PubMed ID: 38941099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity].
    Puig-Junoy J
    Gac Sanit; 2007; 21(1):1-4. PubMed ID: 17306178
    [No Abstract]   [Full Text] [Related]  

  • 33. The costs of compliance with the 1962 FDA amendments.
    Dranove D
    J Health Econ; 1991 Jul; 10(2):235-8. PubMed ID: 10113011
    [No Abstract]   [Full Text] [Related]  

  • 34. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study.
    Moore TJ; Heyward J; Anderson G; Alexander GC
    BMJ Open; 2020 Jun; 10(6):e038863. PubMed ID: 32532786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
    Andersson F
    Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost of drug development: a systematic review.
    Morgan S; Grootendorst P; Lexchin J; Cunningham C; Greyson D
    Health Policy; 2011 Apr; 100(1):4-17. PubMed ID: 21256615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014.
    Wouters OJ; Kesselheim AS; Kuha J; Luyten J
    Value Health; 2024 Oct; 27(10):1373-1381. PubMed ID: 38977188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
    Giri I; Rouillon F
    Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
    [No Abstract]   [Full Text] [Related]  

  • 40. [The economics of therapeutic investigations (author's transl)].
    Poisvert M
    Anesth Analg (Paris); 1980; 37(9-10):619-20, 623-6. PubMed ID: 7469079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.